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Background: Andrographis paniculata (andrographis) is one of the herbal products that are widely used for various
indications. Hypersensitivity reactions have been reported among subjects receiving Andrographis paniculata in
Thailand. Understanding of characteristics of patients, adverse events, and clinical outcomes is essential for ensuring
population safety.
This study aimed to describe the characteristics of hypersensitivity reactions reported in patients receiving
andrographis containing products in Thailand using national pharmacovigilance database.
Methods: Thai Vigibase data from February 2001 to December 2012 involving andrographis products were used.
This database includes the reports submitted through the spontaneous reporting system and intensive monitoring
programmes. The database contained patient characteristic, adverse events associated with andrographis products,
and details on seriousness, causality, and clinical outcomes. Case reports were included for final analysis if they met
the inclusion criteria; 1) reports with andrographis being the only suspected cause, 2) reports with terms consistent
with the constellation of hypersensitivity reactions, and 3) reports with terms considered critical terms according to
WHO criteria. Descriptive statistics were used.
Results: A total of 248 case reports of andrographis-associated adverse events were identified. Only 106 case
reports specified andrographis herbal product as the only suspected drug and reported at least one term consistent
with constellation of hypersensitivity reactions.
Most case reports (89%) came from spontaneous reporting system with no previously documented history of drug
allergy (88%). Of these, 18 case reports were classified as serious with 16 cases requiring hospitalization. For final
assessment, the case reports with terms consistent with constellation of hypersensitivity reactions and critical terms
were included. Thirteen case reports met such criteria including anaphylactic shock (n = 5), anaphylactic reaction
(n = 4) and angioedema (n = 4). Time to development of symptoms ranged from 5 minutes to 1 day. The doses of
andrographis used varied from 352 mg to 1,750 mg. Causality assessment of 13 case reports were certain (n = 3),
probable (n = 8) and possible (n = 2).
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Conclusions: Our findings suggested that hypersensitivity reactions have been reported among patients receiving
Andrographis paniculata. Healthcare professionals should be aware of this potential risk. Further investigation of the
causal relationship is needed; meanwhile including hypersensitivity reactions for andrographis product labeling
should be considered.
Keywords: Andrographis paniculata, Database, Health Product Vigilance Center (HPVC), Hypersensitivity Reactions,
ThailandBackground
Andrographis paniculata (andrographis) is one of the
herbal products that have been widely used for a variety
of medical purposes. It is widely found and cultivated in
tropical and subtropical Asia, South-East Asia, and
India. The leave part has been used traditionally to treat
fever, and infection especially those related to respiratory
tract infections [1]. A systematic review of safety and ef-
ficacy of andrographis from seven double-blinded, con-
trolled trials indicated a superiority in alleviating the
subjective symptoms of uncomplicated upper respiratory
tract infection of andrographis compared with placebo
[1]. Mild and infrequent adverse events were reported
following its use [1]. However, the interpretation of
safety data should be cautious from efficacy trials due to
of the absence of rigorous data collection on adverse
events [1]. Additionally, the Uppsala Monitoring Centre
(UMC) which maintains the WHO international phar-
macovigilance programme in collaboration with other
112 countries around the world collected 19 case re-
ports of suspected adverse reactions from andrographis
containing oral products [2]. Of those, 17 reports con-
cerned acute hypersensitivity reactions which included 7
reports of anaphylaxis. Even though andrographis product
is often perceived as a safe herbal product with minor ad-
verse effects, it is recommended that a warning be included
in the product information of andrographis containing oral
products [2].
In Thailand, a single ingredient product of andrographis
in oral preparation forms such as capsule, tablet and bolus
has been listed in the National List of Essential Medicines
(NLEM) for use in the indication of non-infectious diar-
rhea and pharyngotonsillitis since 1999 [3]. Its indication
has been expanded to common cold since 2006 [4,5]. To
ensure its safety, an intensive monitoring programme was
developed as a part of NLEM standard process in order to
surveillance for adverse events that might occur. The pro-
gram was responsible by The Health Product Vigilance
Center (HPVC), which was established under the Thai
Food and Drug Administration, Ministry of Public Health
in 1983 (http://thaihpvc.fda.moph.go.th). Under this inten-
sive monitoring programme, 1,873 patients using androgra-
phis oral containing products (199 during 2001–2003, and
1,674 during 2007–2009) were reported that andrographiscould possibly cause various adverse events such as rash,
pruritus, breath discomfort, cough, peeling skin, fatigue,
nausea, gastric discomfort, anorexia, headache and palpita-
tion [6,7]. It should be noted that direct causation has not
been substantiated and other contributing factors could be
playing a role in adverse events being reported. After this
period, the HPVC has continued monitoring the safety of
this product through spontaneous reporting system. Des-
pite some limitations such as under-reporting and limited
quality of reports, the spontaneous reporting system is still
a valuable mechanism in identifying adverse events and
their characteristics which may lead to regulatory actions to
improve patient safety [8-11].
Thai Vigibase has been developed by the HPVC as the
Thai national database collecting all case reports submit-
ted from the spontaneous reporting system or intensive
monitoring programmes [12]. Intensive monitoring pro-
grammes were undertaken to promote the reporting of
adverse events associated with herbal product use. After
a total of five single herbal products were included in
the Thai NLEM in 1999, a 2-year intensive monitoring
programme of these products was launched in the year
2000. In addition, an intensive monitoring programme
was initiated by the Department for Development of
Thai Traditional and Alternative Medicine (which is re-
sponsible for promoting the use of herbal products in
Thailand). This programme focused on four single
herbal products (Cissus quadrangularis [Veld grape],
Centella asiatica [Pennywort], Derris scandens [Jewel
vine], Momordica charantia [Bitter melon]) that were
under consideration for inclusion in the NLEM. Data
collected under this programme will be crucial informa-
tion used for considering whether these products are to
be listed in NLEM. Suspected adverse events have been
reported by healthcare professionals from more than
900 health facilities in Thailand to the HPVC. The sub-
mission process can be either via an adverse event
reporting form or via an online reporting system. Cur-
rently, Thai Vigibase has contained over 500,000 reports
[13]. Until now, there have been only two published
studies [14,15] using Thai Vigibase. Since Thai Vigibase
has been considered a valuable source to look into ad-
verse event reports among herbal products [14], charac-
terizing patients and adverse events associated with
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standing of this product safety profile. This retrospective
database study aimed to describe characteristics of pa-
tients and hypersensitivity reactions associated with
andrographis containing products using the Thai Vigibase
database.Methods
Data source
This retrospective database study used the Thai Vigibase
which included all case reports of suspected adverse
events submitted by healthcare professionals throughout
the country to HPVC from February 2001 to December
2012. The case reports were obtained through either the
spontaneous reporting system or intensive monitoring
programmes [12]. Since this is an aggregate analysis of
spontaneous reports of adverse events submitted to
HPVC, there is minimal risk of patient confidentiality
breaching. As we did not obtain the consent, we present
specific cases with only general demographic characteris-
tics to ensure patient identity anonymous. Permission for
database access and publication of this work was granted
by Thai FDA.Figure 1 Flow diagram for case reports selection.Criteria for the selection of cases
Reports with andrographis being the only suspected
cause were selected. To be specific in final analysis, we
investigated in details only those reports with terms con-
sistent with constellation of hypersensitivity reactions
[16] and considered critical terms according to WHO
criteria [17].
Data extraction
All reports that indicated andrographis as the only sus-
pected drug were retrieved. Of those reports, only ones
that represented at least one hypersensitivity reaction
[16] based on inclusion criteria were extracted. Finally,
we matched hypersensitivity reaction with the WHO
Adverse Reaction Terminology (WHO-ART) classifica-
tion. According to WHO-ART classification, each pre-
ferred term is categorized into a primary system organ
class and up to two subsidiary system organ classes [17].
We used the matched pair of the primary system organ
class and preferred term in our analysis. A unique
HPVC number identified each unique report. From each
report, the following information was extracted: patient
demographics, co-morbidities, suspected reactions, sus-
pected drug as well as concomitant treatments, dosage,
Table 1 Characteristics of patients and adverse event
reports among andrographis products users
Characteristics No. (%) [n = 106]a
Patients
Sex
Female 76 (71.7)
Male 30 (28.3)
Age [y], mean (SD) [min – max] 38.5 (18.4) [8 – 80]
<15 11 (10.4)
15-30 26 (24.5)
31-60 49 (46.2)
>60 11 (10.4)
N/A 9 (8.5)
History of drug allergy
No 93 (87.7)
Yes 12 (11.3)
N/A 1 (1.0)
Adverse event reports
Source of reports
Spontaneous 95 (89.6)
Intensive 11 (10.4)
Seriousness
Serious 18 (17.0)
Hospitalization or prolongation
of hospitalization
16
Life threatening 2
Non-serious 88 (83.0)
Causality assessmentb
Certain 8 (7.5)
Probable 61 (57.6)
Possible 33 (31.1)
Unlikely 0 (0.0)
N/A 4 (3.8)
No. of concomitant drug, mean (SD) [min – max] 0.4 (0.8) [0 – 4]
None 82 (77.4)
1item 13 (12.3)
2items 7 (6.6)
3items 3 (2.8)
≥4items 1 (0.9)
Time of exposure (day), mean (SD) [min – max] 1.2 (3.4) [0 – 30]
1 day 51 (48.1)
2 days 20 (18.9)
3 days 14 (13.2)
≥4 days 8 (7.6)
N/Ac 13 (12.2)
Table 1 Characteristics of patients and adverse event
reports among andrographis products users (Continued)
Time to onset (day), mean (SD) [min – max] 0.8 (1.6) [0 – 8]
First day of use 61 (57.6)
2daysof use 24 (22.6)
3 days of use 15 (14.2)
≥4 days of use 5 (4.7)
N/A 1 (0.9)
aAll 106 reports contained hypersensitivity reactions and an andrographis
product was considered as the sole suspected drug.
bAs per reported from health professional.
cSome reports had no information on starting date, stopping date, or both.
N/A = not available.
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event onset, clinical outcome, causality assessment, and
the source of reports. The seriousness of adverse event
was classified as non-serious and serious events. For serious
adverse events, they were sub-classified into hospitalization
or prolongation of hospitalization, persistent or significant
disability/incapacity, and life threatening. Data in Thai Vigi-
base were in the Oracle® format.
Data analyses
The data were managed using Microsoft Excel® and sub-
sequently imported into STATA® version 12.0 (Stata-
Corp, College Station, Texas) for analysis. All variables
were analyzed using descriptive statistics to determine
total number of reports; mean age and number in each
age group; percentage of gender, history of drug allergy,
distribution of adverse events, source of reports, causal-
ity assessment, time of exposure, number of concomi-
tant treatments, and time to onset of reaction.
Results
A total of 197 case reports of adverse events associated
with Andrographis paniculata containing products were
retrieved. In all reports, the herbal product was taken by
mouth and was sole suspected drug in 170 case reports.
A total of 106 cases reported term (s) consistent with
constellation of hypersensitivity reactions (Figure 1).
Characteristics of 106 cases were provided in Table 1.
Most of them (89.6%) came from spontaneous reporting
system. Age ranged from 8 – 80 years with a mean age of
38.5 ± 18.4 years old and 71.7% were female. Almost half
of them (46.2%) were in 31–60 years age group. Eighty-
seven percent had no previously documented history of
drug allergy. Only 17% (18 cases) were classified as serious
with 16 cases requiring hospitalization. None of these re-
sulted in death. For the causal relationship of reported
event and the suspected herbal drugs, 57.6% were assessed
as probable, followed by possible 31.1% and certain 7.5%.
Most of them (77.4%) were no concomitant drug. Forty-
eighth percent had time of exposure less than 1 day. The
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in 57.6% of case reports and 22.6% on the second days of
use. The reported adverse events were shown in Table 2.
Out of 106 case reports, a total of 13 case reports were
included for detail case description since their reactions
were hypersensitivity reactions considered critical term
according to WHO criteria. Adverse events included
anaphylactic shock (5), anaphylactic reaction (4) and an-
gioedema (5). The average age was 38.9 years old. Most
of them (10/13, 76.9%) were female. Details of each case
including adverse event reports were shown in Table 3.
A history of drug allergy was present in two patients
who developed angioedema. One patient was allergic to
tetracycline, while another one was allergic to ibuprofen.
The onset ranged from 5 minutes to 1 day. Most of them
(11 case reports) were serious. The probability of causality
assessment was certain (3), probable (7) and possible (1).
Of 13 case reports, 7 case reports indicated the product’s
brand name. Most importantly, 6 brands were reported
among the 7 case reports. After checking each brand
name, all of them are dry powder with different doses ran-
ging from 352 mg to 1,750 mg.
Discussion
Our study is the first report accumulating a number of
case reports with hypersensitivity reactions especially
anaphylactic reactions among andrographis users in
Thailand. Our findings indicated that the oral use of
andrographis may be associated with a risk of acute hyper-
sensitivity reactions. However, it was not possible to draw
a direct causal relation from this study. There remains aTable 2 Adverse events classified by organ system according
System organ class No. (%) [n = 243]a Preferred term(n
Skin and appendages disorders 126(51.85) Urticaria (37), rash
dermatitis exfolia
increased (2), acu
eosinophillia (1),
Body as a whole-general disorders 57(23.46) Face oedema (19
fatigue (6), oedem
(1), therapeutic re
Gastrointestinal system disorders 22(9.05) Nausea (8), vomit
disorder non-spe
Respiratory system disorders 15(6.17) Dyspnoea (6), cou
Psychiatric disorders 8(3.29) Anorexia (4), som
Central and peripheral nervous
system disorders
7(2.88) Headache (3), dys
Musculoskeleton system disorders 3(1.23) Muscle weakness
Vascular (extra cardiac) disorders 1(0.41) Vasculitis (1)
Liver and biliary system disorders 1(0.41) Hepatitis(1)
Urinary system disorders 1(0.41) Urinary frequency
Various 2(0.82) Anaesthesia local
aNumber of events from 106 case reports (some reports have more than one event
Bold indicates hypersensitivity reactions with critical term.strong need warranting a further study to investigate this
association in the future.
Even though andrographis had long been used as trad-
itional medicines particularly in Southeast Asia, e.g.
India, Thailand, there has been limited report about
hypersensitivity reaction associated with andrographis.
To the best of our search, there was only one study [18]
reporting a case of anaphylactic reaction among an HIV
patient. This study was conducted in 13 HIV positive pa-
tients and 5 uninfected health-volunteer to evaluate ad-
verse events of escalating dosages. At the elevated dose
of andrographis (6–12 times higher than usual dose), a
case of HIV patient experienced an anaphylactic reaction
during week 4 and stopped medication. It is not uncom-
mon to expect such adverse event when any particular
product is given in such circumstance. It was important
to note that there was no mention on the mechanism of
such hypersensitivity reaction.
The number of cases reports of hypersensitivity analysis
among andrographis users in this study was 106, which
was much higher than 17 cases reported in the first docu-
ment describing the international experiences in pharma-
covigilance network [2]. In addition, these reports were
submitted from various settings with differing brand prod-
ucts. This cumulative evidence suggested that andrographis
was potentially associated with hypersensitive reactions as
it was the likely cause for the majority of cases.
It is important to note that all case reports in this
study used andrographis containing product as a single
agent. This is very different from others [2]. Farah et al.
[2] described 17 reports of hypersensitivity reactionsto WHO Adverse Reaction Terminology
)
maculo-papular (31), rash (18), pruritus (16), rash erythematous (8),
tive (1), skin exfoliation (2), Steven Johnson syndrome (1), sweating
te generalized exanthematous pustulosis (1), bullous eruption (1),
fixed eruption (1), stomatitis ulcerative (1), purpura allergic (1), flushing (1)
), angioedema (4), anaphylactic shock(5), anaphylactic reaction (4),
a mouth (5), fever (3), chest pain (3), oedema (2), oedema periorbital
sponse decreased (2), back pain (1), oedema peripheral(3), pain(1)
ing (4), abdominal pain (2), diarrhea (1), gastro-intestinal
cific (1), lipsdry (1), stomatitis (1), melaena (1), mouth dry (1)
ghing (6), bronchospasm (2), sputum increased (1)
nolence (3), insomnia(1)
aethesia (2), dizziness(2)
(2), paralysis (1)
(1)
(1), anaesthesia mouth(1)
).
Table 3 Hypersensitivity reactions with critical term among patients using andrographis product
Case no.
Product Adverse event/symptom
Outcome
Drug Typea Dosage Adverse event Details Onset Seriousness
Causality
assessment
1 andrographis (325 mg/cap) S 5 cap PO, OD anaphylactic shock Angioedema,
urticaria, BP 90/60
30 min serious (hospitalization or
prolongation of hospitalization)
Certain Complete recovery
without lesion
2 andrographis (352 mg/cap) S 3 cap 1 time used anaphylactic shock Urticaria, BP 87/73 1 day serious (hospitalization or
prolongation of hospitalization)
Probable Complete recovery
without lesion
paracetamol (500 mg) O 1 tab PO, OD
chlorpheniramine (4 mg) O 1 tab PO, TID
3 andrographis S 2 cap 1 time used anaphylactic shock Urticaria, BP 90/70 30 min serious (hospitalization or
prolongation of hospitalization)
Probable Complete recovery
without lesion
paracetamol (500 mg) O 2 tab PO, prn
4 andrographis S 2 cap 1 time used anaphylactic shock Oedema, uticaria,
chest pain, BP 130/70
1 day serious (hospitalization or
prolongation of hospitalization)
Probable Complete recovery
without lesion
5 andrographis (352 mg/cap) S 1 cap PO, TID anaphylactic shock Puffy eyelid, lung
wheezing, drowsiness,
BP 80/50
1 day serious (life threatening) Certain Complete recovery
without lesion
6 andrographis S 1750 mg 1 time used anaphylactic reaction Urticaria, sweat increased,
nausea, BP 96/59
10 min serious (hospitalization or
prolongation of hospitalization)
Probable Complete recovery
without lesion
7 andrographis S 350 mg PO, 1 time used anaphylactic reaction anaphylactic reaction,
BP 120/80
45 min serious (life threatening) Probable Complete recovery
without lesion
8 andrographis S 400 mg 2 time used anaphylactic reaction Oedema eyelid, wheezing,
rash, BP 153/101
16 hr serious (hospitalization or
prolongation of hospitalization)
Probable Complete recovery
without lesion
9 andrographis S 2 cap PO, 1 time used anaphylactic reaction Urticaria, rash, chest
tightness, , tachycardia
5 min serious (hospitalization or
prolongation of hospitalization)
Probable Complete recovery
without lesion
10 andrographis S 4 cap PO, TID angioedema Angioedema, urticaria 1 day Non-serious Certain Complete recovery
without lesion
11 andrographis S 3 cap PO, TID angioedema - 1 day Non-serious Possible Complete recovery
without lesion
guaifenesin (100 mg) O 1 tab PO, TID
Salbutamol (4 mg) O 1 tab PO, TID
12 andrographis S N/A angioedema - N/A Non-serious Possible Complete recovery
without lesion
ranitidine O N/A
hydrochlorothiazide O N/A
Curcuma longa Linn. O N/A
13 andrographis S N/A angioedema - 1 day Non-serious Probable Still has some
symptom
aS = Suspected product, O = Other product.
Abbreviations: PO Per oral, OD once a day, TID three times a day, QIDQuater In Die (four times a day), prn Pro Re Nata (as needed), N/A not available, minminute (s), hr hour (s).
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ports consist of both single agent and combination of
agents in products containing andrographis. It was sug-
gested that the use andrographis as a single agent or
purified form as andrographolide should be prohibited.
Calabrese et al. [18] hypothesised that this herb has been
used in combination with other herbs, perhaps to ameli-
orate potential adverse effects from andrographis.
The issue of reporting of hypersensitivity reactions
among andrographis users has caught attention of Thai
FDA. The Signal Detection and Assessment Working
Group and Drug Safety (pharmacovigilance) subcommit-
tee under Thai FDA decided to make no changes on
product labelling because the causation could not be
confirmed. The report of potential association was dis-
seminated through HPVC (Health Products Vigilance
Center) safety news. In addition, Thai FDA recommends
a pharmacoepidemiology study to determine whether
the association between hypersensitivity reactions and
andrographis containing products is confirmed.
An important limitation of current evidence is the lack
of direct causation. Our study cannot eliminate a possi-
bility that hypersensitivity reaction might be related to
product contamination and its lack of standardization
across brands. Even though the evidence presented in
this article is substantiated with a large number of case
reports submitted from various settings with differing
brand products, there remains no direct causation study
that can make such a conclusive remark.
Conclusion
In summary, our findings demonstrated that hypersensi-
tivity reactions have been reported among patients receiv-
ing Andrographis paniculata. Healthcare professionals
should be aware of this potential risk. Further investiga-
tion of the causal relationship is needed.
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